

Recyclization of the Products of Amidine Addition to the Substituted 5-Amino-4-cyano-1,3-oxazole into New Derivatives of 5,6-Diaminopyrimidin-4-one

A. P. Kozachenko^a, O. V. Shablykin^a, A. N. Vasilenko^a,
E. B. Rusanov^b, V. S. Brovarets^a, and B. S. Drach^{† a}

^a Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine,
ul. Murmanskaya 1, Kiev, 02660 Ukraine
e-mail: brovarets@bpci.kiev.ua

^b Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Kiev, Ukraine

Received September 1, 2009

Abstract—The products of addition of amidines to accessible 5-arylamino-4-cyano-1,3-oxazoles at heating in acetic acid undergo recyclization and afford new derivatives of 6-amino-5-acylaminopyrimidin-4-one, whose structure was reliably established using X-ray diffraction studies.

DOI: 10.1134/S1070363210050233

Derivatives of 5,6-diaminopyrimidin-4-one arise permanent interest in synthetic chemistry as biologically active substances and as intermediates in the synthesis of purine bases [1–7]. Despite the fact that chemical derivatives of 5,6-diaminopyrimidine have been well studied [8], some of these compounds are produced by a complex way, or are not known. Therefore the search for original, accessible initial substrates for the synthesis of new representatives of the 5,6-diaminopyrimidin-4-one derivatives is an important task.


In this paper we report on a method for obtaining previously unknown derivatives of 5,6-diaminopyrimidin-4-one with aryl substituents in positions 2 and 3 of the pyrimidine ring by recyclization of the products of addition of amidines to accessible 5-arylamino-4-cyano-1,3-oxazoles (**I**) [9] by heating them in acetic acid (Scheme 1). The initial stage of this process is the addition of amidines to the nitrile group of compounds **I**, which like with other nitrile [10, 11] proceeds with the formation of substrates **II**. The latter were isolated in individual state (Table 1). The structure of adducts **II** was reliably proved by the data of elemental analysis, mass spectra, and IR spectra, in the latter was lacking the band of stretching vibrations of the cyano group (Table 2). At the same time the

comparison of ¹³C NMR spectra of the compounds **Id** and **IIh** (Fig. 1) suggests that oxazole cycle remains intact at the **I** → **II** transformation.

The products **II** contain labile hydrogen atoms and therefore are able of prototropism with the formation of non-aromatic tautomers **III** containing unsaturated 5-imino azlactone system. At heating the latter in 98% acetic acid the azlactone system is cleaved by water, and thus further intramolecular **IV** → **V** cyclization is provided (Scheme 1).

Similar intramolecular cyclization with splitting off the ammonia molecule and the formation of the pyrimidine ring is known for a number of compounds with a characteristic fragment **A** [12, 13].

The structure of the final products of this complex



II → **V** transformation agrees with the mass spectra that contain a molecular peak greater by unity than for the substrates **II**. The elemental analysis data also indicate that formation of compounds **V** includes splitting off ammonia from the product **II** and adding a water molecule.

[†] Deceased.

Table 1. Yields, melting points, data of elemental analysis, and mass spectra of compounds **II** and **V**

Comp. no.	Yield, %	mp, °C	Found, %			Formula	Calculated, %			M^+
			C	H	N		C	H	N	
IIa	52	167–170	72.97	5.27	17.65	C ₂₄ H ₂₁ N ₅ O	72.89	5.35	17.71	395
IIb	81	200–202	73.24	5.73	17.19	C ₂₅ H ₂₃ N ₅ O	73.33	5.66	17.10	409
IIc	78	197–199	60.86	4.30	14.74	C ₂₄ H ₂₀ BrN ₅ O ^a	60.77	4.25	14.76	473; 475
IId	68	203–205	60.83	4.32	14.82	C ₂₄ H ₂₀ BrN ₅ O ^b	60.77	4.25	14.76	473; 475
IIe	50	193–195	73.26	5.75	17.02	C ₂₅ H ₂₃ N ₅ O	73.33	5.66	17.10	409
IIf	84	192–194	73.66	5.87	16.64	C ₂₆ H ₂₅ N ₅ O	73.74	5.95	16.54	423
IIh	73	208–209	61.42	4.61	14.27	C ₂₅ H ₂₂ BrN ₅ O ^c	61.48	4.54	14.34	487; 489
IIh	64	138–140 ^d	68.35	5.66	21.09	C ₁₉ H ₁₉ N ₅ O	68.45	5.74	21.01	333
Va	86	125–128	72.63	5.01	14.08	C ₂₄ H ₂₀ N ₄ O ₂	72.71	5.08	14.13	396
Vb	94	241–243	73.07	5.48	13.74	C ₂₅ H ₂₂ N ₄ O ₂	73.15	5.40	13.65	410
Vc	91	267–269	60.73	4.10	11.88	C ₂₄ H ₁₉ BrN ₄ O ₂ ^e	60.64	4.03	11.79	474; 476
Vd	81	284–286	60.57	3.96	11.69	C ₂₄ H ₁₉ BrN ₄ O ₂ ^f	60.64	4.03	11.79	474; 476
Ve	82	199–201	73.24	5.49	13.72	C ₂₅ H ₂₂ N ₄ O ₂	73.15	5.40	13.65	411
Vf	95	218–220	73.63	5.65	13.15	C ₂₆ H ₂₄ N ₄ O ₂	73.57	5.70	13.30	425
Vg	88	267–269	61.42	4.42	11.37	C ₂₅ H ₂₁ BrN ₄ O ₂ ^g	61.36	4.33	11.45	488; 490
Vh	70	291–293	68.34	5.49	16.72	C ₁₉ H ₁₈ N ₄ O ₂	68.25	5.43	16.76	335


^a Found, %: Br 16.93. Calculated, %: Br 16.84. ^b Found, %: Br 16.92. Calculated, %: Br 16.84. ^c Found, %: Br 16.28. Calculated, %: Br 16.36. ^d After recrystallization from acetonitrile. ^e Found, %: Br 16.89. Calculated, %: Br 16.81. ^f Found, %: Br 16.73. Calculated, %: Br 16.81. ^g Found, %: Br 16.42. Calculated, %: Br 16.33.

Table 2. Spectral data of synthesized compounds

Comp. no.	IR spectrum (KBr), ν , cm ⁻¹	¹ H NMR spectrum (DMSO- <i>d</i> ₆), δ , mmp
IIa	1676 (C=N) ^a , 2200–2300 (bands not observed), 3050–3500 (NH as.)	2.29 s (3H, CH ₃), 7.09–7.93 m (14H arom.), 8.80 br.s (1H, NH) ^b
IIc	1675 (C=N) ^a , 2200–2300 (bands not observed), 2950–3430 (NH as.)	2.27 s (3H, CH ₃), 7.10–7.88 m (13H arom.), 8.79 br.s (1H, NH) ^b
IIe	1681 (C=N) ^a , 2200–2300 (bands not observed), 3000–3420 (NH as.)	2.29 s (3H, CH ₃), 2.35 s (3H, CH ₃), 7.08–7.94 m (13H arom.), 8.78 br.s (1H, NH) ^b
IIg	1677 (C=N) ^a , 2200–2300 (bands not observed), 3000–3450 (NH as.)	2.29 s (3H, CH ₃), 2.35 s (3H, CH ₃), 7.08–7.89 m (12H arom.), 8.74 br.s (1H, NH) ^b
IIh	1674 (C=N) ^a , 2200–2300 (bands not observed), 3020–3460 (NH as.)	2.14 s (3H, CH ₃), 2.24 s (3H, CH ₃), 7.03–7.14 m (4H arom.), 7.46–7.94 m (5H arom.), 8.43 br.s (1H, NH) ^b
Va	1642 (C=O) ^a , 3010–3362 (NH as.)	2.24 s (3H, CH ₃), 6.49 br.s (2H, NH ₂), 7.01–8.00 m (14H arom.), 9.16 s (1H, NH)
Vb	1643 (C=O) ^a , 3143–3397 (NH as.)	2.23 s (3H, CH ₃), 2.25 s (3H, CH ₃), 6.46 br.s (2H, NH ₂), 6.98–7.99 m (13H arom.), 9.15 s (1H, NH)
Vc	1638 (C=O) ^a , 3170–3311 (NH as.)	2.27 s (3H, CH ₃), 6.52 br.s (2H, NH ₂), 7.02–7.52 m (13H arom.), 9.17 s (1H, NH)
Vd	1650 (C=O) ^a , 3049–3410 (NH as.)	2.38 s (3H, CH ₃), 6.52 br.s (2H, NH ₂), 7.15–7.90 m (13H arom.), 9.08 s (1H, NH)
Ve	1649 (C=O) ^a , 3061–3297 (NH as.)	2.23 s (3H, CH ₃), 2.38 s (3H, CH ₃), 6.59 br.s (2H, NH ₂), 7.03–7.94 m (13H arom.), 9.15 s (1H, NH)
Vf	1651 (C=O) ^a , 2917–3355 (NH as.)	2.23 s (3H, CH ₃), 2.26 s (3H, CH ₃), 2.38 s (3H, CH ₃), 6.42 br.s (2H, NH ₂), 6.98–7.90 m (12H arom.), 9.06 s (1H, NH)
Vg	1632 (C=O) ^a , 3040–3480 (NH as.)	2.27 s (3H, CH ₃), 2.38 s (3H, CH ₃), 6.47 br.s (2H, NH ₂), 7.02–7.90 m (12H arom.), 9.08 s (1H, NH)
Vh	1645 (C=O) ^a , 2984–3421 (NH as.)	1.98 s (3H, CH ₃), 2.22 s (3H, CH ₃), 6.43 br.s (2H, NH ₂), 7.00–7.28 m (9H arom.), 8.76 s (1H, NH)

^a Band with shoulder. ^b In exchange for NH, NH₂.

Scheme 1.



I: R = Ph, Ar = 4-MeC₆H₄ (**a**); R = 4-MeC₆H₄, Ar = Ph (**b**); R = 4-MeC₆H₄, Ar = 4-MeC₆H₄ (**c**); R = Me, Ar = 4-MeC₆H₄ (**d**); **II-V**: R = Ar¹ = Ph, Ar = 4-MeC₆H₄ (**a**); R = Ph, Ar = Ar¹ = 4-MeC₆H₄ (**b**); R = Ph, Ar = 4-MeC₆H₄, Ar¹ = 4-BrC₆H₄ (**c**); R = 4-MeC₆H₄, Ar = Ph, Ar¹ = 4-BrC₆H₄ (**d**); R = Ar = 4-MeC₆H₄, Ar¹ = Ph (**e**); R = Ar = Ar¹ = 4-MeC₆H₄ (**f**); R = Ar = 4-MeC₆H₄, Ar¹ = 4-BrC₆H₄ (**g**); R = Me, Ar = 4-MeC₆H₄, Ar¹ = Ph (**h**).

The ¹H NMR spectra of compounds **V** contain the signals of the amide and the primary amino group protons in typical positions (9.06–9.16 and 6.42–6.52 ppm, respectively). Furthermore, the comparison

of the ¹³C NMR spectra of compounds **IIh** and **Vh** indicates the transformation of oxazole ring (cf. the signals of carbon atoms of the methyl group in Fig. 1).




Fig. 1. Fragments of ¹³C NMR spectra of compounds **Id**, **IIh**, and **Vh**.




Fig. 2. The main correlations (shown by arrows) and the assignment of signals (ppm) in the ¹H and ¹³C NMR spectra of compound **Ve**.

An important confirmation of the structure of compounds **V** was also obtained by a comprehensive analysis using two-dimensional NMR spectroscopy, which included homonuclear experiments COSY and NOESY, and heteronuclear HMBC and HMQC. Basic correlations for compound **Ve** are shown in Fig. 2, and all the found correlations are listed in Table 3. The two-dimensional HMBC spectrum revealed the interaction of the CONH proton (9.14 ppm) with the carbon nuclei CONH (166.39 ppm), C^{5a} (97.15 ppm), C^{4a} (160.27 ppm) and C^{6a} (158.41 ppm), proving the cleavage of the oxazole cycle.

But all these data are still not sufficient to exclude other alternative structures. Therefore, for the unequivocal proof of the structure of compounds **V**, one of them (R = Ar = 4-MeC₆H₄, Ar¹ = Ph) was used for the X-ray diffraction analysis (Fig. 3). The distribution of bond lengths and angles in the pyrimidine cycle has no special features and is characteristic of such systems (Fig. 3). The heterocycle is almost planar, the mean deviation of atoms from the mean plane is 0.016 Å. Phenyl groups C¹³–C¹⁸ and C²⁰–C²⁵ at the heterocycle

are turned by 82° and 72° respectively. The bonds C²N³ 1.352(3) and C⁵N⁴ 1.350(3) Å are significantly shorter compared with the standard [14] length of a single C–N bond (average 1.45 Å), which is associated with conjugation of the lone electron pair of nitrogen atoms N³ and N⁴ with the π-system of the heterocycle and the carbonyl bond, respectively.

The compound **Ve** crystallizes with one molecule of water. In the crystal a formation of the hydrogen bonds O³–N³¹⁰...O¹ and N³–H^{31N}...N² is observed with the following parameters: O³H³¹⁰ 0.83(4), O³...O¹ 2.9545(18) Å, O³–H³¹⁰–O¹ 143(4)°, and N³–H^{31N} 0.90(3), N³...N² 3.038(3) Å, N³–H^{31N}–N² 173(2)°.

Since the intermediate compounds **IV** were not identified, it is possible that the synthesis of compounds **V** can also proceed along the path **II** → **VI** → **VII** → **V** (Scheme 2). A key role in this transformation play compounds **VII**, which are unstable in acidic medium and can be easily split with water like other oxazole[5,4-*d*]pyrimidines [15,16], but we believe that the preferable way of the formation of compounds **V** is the one shown in Scheme 1.

Table 3. The list of correlations in the COSY, NOESY, HMQC, and HMBC spectra of compound **Ve**^a

¹ H, δ	¹ H, δ		¹³ C, δ(C ^{3b} H, C ^{5b} H)	
	COSY	NOESY	HMQC	HMBC
7.23 (C ^{4b} H)	7.33	7.33	129.76	129.27 (C ^{2b} , C ^{6b})
7.33 (C ^{3b} H, C ^{5b} H)	7.23, 7.25	7.23, 7.25	129.37	129.37 (C ^{3b} , C ^{5b}), 135.94 (C ^{1b})
7.25 (C ^{2b} H, C ^{6b} H)	7.33	7.33	129.27	129.27 (C ^{2b} , C ^{6b}), 157.60 (C ^{2a}), 129.76 (C ^{4b})
6.59 (NH ₂)	—	—	—	—
2.37 (CH ₃ C ^{4c})	—	7.30	21.70	141.71 (C ^{4c}), 128.30 (C ^{3c} , C ^{5c})
7.30 (C ^{3c} H, C ^{5c} H)	7.92	7.92, 2.37	128.30	128.30 (C ^{3c} , C ^{5c}), 21.70 (CH ₃ C ^{4c}), 132.47 (C ^{1c})
7.92 (C ^{2c} H, C ^{6c} H)	7.30	7.30, 9.14	128.66	128.66 (C ^{2c} , C ^{6c}), 166.39 (CONH)
9.14 (CONH)	—	7.92	—	166.39 (CONH), 97.15 (C ^{5a}), 160.27 (C ^{4a}), 158.41 (C ^{6a})
2.23 (CH ₃ C ^{4d})	—	7.08	21.29	129.67 (C ^{3d} , C ^{5d}), 137.92 (C ^{4d})
7.08 (C ^{3d} H, C ^{5d} H)	7.04	2.23, 7.04	129.67	135.82 (C ^{1d}), 21.29 (CH ₃ C ^{4d}), 129.67 (C ^{3d} , C ^{5d})
7.04 (C ^{2d} H, C ^{6d} H)	7.08	7.08	129.84	137.92 (C ^{4d}), 129.84 (C ^{2d} , C ^{6d})

^a For the numbering of carbon atoms see Fig. 2.


In conclusion, we note that the transformation of compounds **I** → **V** is of interest not only as an unusual transformation of the oxazole ring into the pyrimidine one, but also as a preparative method of synthesis of previously unknown derivatives of 5,6-diaminopyrimidin-4-one, the intermediates in the synthesis of purine bases. Their possible use in this direction will be considered by us in the future.

EXPERIMENTAL

The IR spectra of the compounds were recorded on a Vertex 70 spectrometer from tablets with KBr, the ¹H NMR spectra were taken on a Varian-300 instrument, and the ¹H and ¹³C NMR spectra of compounds **Id**, **Ih**, **Vh**, and **Ve**, on a Varian Mercury-400 instrument in DMSO-*d*₆ with internal reference TMS. The mass spectra of compounds were recorded on an Agilent

1100/DAD/MSD VL G1965 instrument. The melting points were measured on a Fisher–Johns unit.

The X-ray diffraction study of a single crystal of compound **Ve** with linear dimensions 0.04×0.08×0.46 mm was carried out at room temperature on a Bruker Smart Apex II diffractometer (λMoK_α radiation, graphite monochromator, θ_{max} 26.40°, sphere segment −15 ≤ *h* ≤ 8, −7 ≤ *k* ≤ 7, −36 ≤ *l* ≤ 37). Overall number of measured reflections 12,733, of which 4,573 were independent (*R*-factor of averaging 0.0532). Crystals of compound **Ve**: C₂₅H₂₃N₄O_{2.5}, *M* = 419.47, are monoclinic, space group *P2*/*c*, *a* = 12.0149(7), *b* = 6.1862(4), *c* = 30.3489(17) Å, β = 97.266(3)°, *V* = 2237.6(2) Å³, *Z* = 4, *d*_{calc} = 1.245, μ = 0.082 mm^{−1}, *F*(000) = 884. The structure was solved by the direct method and refined by full-matrix least-mean-squares method in an anisotropic approximation using the

Scheme 2.




Fig. 3. General view of the molecule Ve and the main bond lengths and angles.

programs SHELXS97 and SHELXL97 [17, 18]. For the refinement 4573 reflections were used with $I > 2\sigma(I)$, (355 refined parameters, number of reflections per a parameter 12.9, the weight scheme was used, $\omega = 1/[\sigma^2(F_o^2) + (0.0598P)^2]$, where $P = (F_o^2 + 2F_c^2)/3$, the ratio of maximum (average) shift to the error in final cycle was 0.10(0.005). The extinction correction was introduced using the program SADABS (ratio of minimum to maximum corrections $T_{\min}/T_{\max} = 0.656381$). The hydrogen atoms of methyl groups were localized geometrically, other hydrogen atoms were identified and refined isotropically. The final values of divergence factors are as follows: $R1(F) = 0.0531$, $wR2(F^2) = 0.1085$, $GOF = 0.953$, over the reflections with $I > 2\sigma(I)$. Residual electron density obtained from the difference Fourier series after the last cycle of refinement was 0.18 and $-0.18 \text{ e}/\text{\AA}^3$.

A complete set of X-ray data for compound Ve is deposited in the Cambridge Structural Database (CCDC 742460).

N-[(2-Aryl-5-arylamino-1,3-oxazol-4-yl)(imino)-methyl]arylamidines (IIa–IIh). To a solution of 0.04 mol of oxazole Ia–Id [9] in 10 ml of anhydrous ethanol was added 0.08 mol of arylamidine, the mixture was refluxed for 4 h, the separated orange precipitate was filtered off, washed with ethanol and

water, and a compound IIa–IIh formed was purified by recrystallization from ethanol.

6-Amino-5-acylamino-2,3-diaryl-3H-pyrimidin-4-ones (Va–Vh). A solution of 0.04 mol of a compound IIa–IIh in 20 ml of 98% acetic acid was refluxed for 2 h, 150 ml of water was then added, the precipitate formed was filtered off, and compound Va–Vh formed was crystallized from ethanol–water 9:1 mixture.

REFERENCES

1. Lunt, E., in *Comprehensive Organic Chemistry*, Barton, D. and Ollis, W.D. Eds., London: Pergamon Press, 1979.
2. Kimura, T., Takase, Y., Tanaka, H., Ohtsuka, I., Seeki, T., Kogushi, M., Yamada, T., Fujimori, T., Saitou I., and Akasaka, K., *J. Med. Chem.*, 1993, vol. 36, no. 11, p. 1630.
3. Chorvat, R.J., Bakthavatchalam, R., Beck, J.P., Gilligan, P.J., Wilde, R.G., Cocuzza, A.J., Hobbs, F.W., Cheeseman, R.S., Curry, M., Rescinito, J.P., Krenitsky, P., Chidester, D., Yarem, J.A., Klaczkiwicz, J.D., Hodge, C.N., Aldrich, P.E., Wasserman, Z.R., Fernandez, Ch., Zaczek, R., Fitzgerald, L.W., Huang, Sh.-M., Shen, H.L., Wong, Y.N., Chien, B.M., Quon, Ch.Y., and Arvanitis, A., *J. Med. Chem.*, 1999, vol. 42, no. 5, p. 833.

4. Brakta, M., Murthy, D., Ellis, L., and Phattare, S., *Bioorg. and Med. Chem. Lett.*, 2002, vol. 12, no. 11, p. 1489.
5. Bhushan, R.G. and Vince, R., *Bioorg. and Med. Chem. Lett.*, 2002, vol. 10, no. 7, p. 2325.
6. Biagi, G., Giorgi, I., Leonardi, M., Livi, O., Pacchini, F., Scartoni, V., Costa, B., and Lucacchini, A., *Eur. J. Med. Chem.*, 2003, vol. 38, no. 9, p. 810.
7. Laufer, S.A., Domeyer, D.M., Scior, T.R.F., Albrecht, W., and Hauser, D.R.J., *J. Med. Chem.*, 2005, vol. 48, no. 3, p. 710.
8. Brown, D.J., *The Pyrimidines. In: The Chemistry of Heterocyclic Compounds*, Weissberger, A., Ed., suppl. 2, New York: Wiley, 1985.
9. Kozachenko, A.P., Shablykin, O.V., Rusenov, E.B., Vasilenko, A.N., and Brovarets, V.S., *Zh. Obshch. Khim.*, 2009, vol. 79, no. 5, p. 824.
10. McCasland, G.E. and Torbell, D.S., *J. Am. Chem. Soc.*, 1946, vol. 68, no. 11, p. 2393.
11. Backer, H.J. and Wanmaker, W.L., *Rec. Trav. Chim.*, 1951, vol. 70, p. 638.
12. Takahashi, T., Hirokami, S., Kato, K., Nagata, M., and Yamazaki, T., *J. Org. Chem.*, 1983, vol. 48, no. 17, p. 2914.
13. Shishoo, C.J., Devani, M.B., Ananthan, S., Jain, K.S., Bhadti, V.S., Mohan, S., and Patel, L., *Indian J. Chem., Sect. B*, 1989, vol. 28, p. 1039.
14. Allen, F.H., Kennard, O., Watson, D.G., Brammer, L., Orpen, A.G., and Taylor, R., *J. Chem. Soc., Perkin Trans. 2*, 1987, p. 1.
15. Falco, E.A., Elion, G.B., Burgi, E., and Hitchings, H., *J. Am. Chem. Soc.*, 1952, vol. 74, no. 19, p. 4897.
16. Melik-Ogandzhanyan, R.G., Khachaturyan, T.A., Mirzoyan, V.S., and Arsenyan, F.G., *Khim. Geterotsikl. Soedin.*, 1983, no.1, p. 112.
17. Sheldrick, G.M., *SHELXS97, Program for the Solution of Crystal Structure*, University of Göttingen, Göttingen, 1997.
18. Sheldrick, G.M., *SHELXL97, Program for the Refinement of Crystal Structures*, University of Göttingen, Göttingen, 1997.